Viking Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| Operating income | -$393.3 | -$150.9 | -$100.8 | -$70.4 | -$55.7 |
| Net income | -$359.6 | -$110.0 | -$85.9 | -$68.9 | -$55.0 |
| Cash Flow Statement | |||||
| Share repurchases | — | — | — | $6.8 | — |
Shares outstanding 116.7M · Free float 91.0%
Annual filing data through FY ended December 31, 2025; float as of September 11, 2026.
Earnings
Other Coverage
October 14, 2026
Theme Survey
GLP-1 companies reshape access and detail treatment dropouts
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 23, 2026
Drug Pipeline
Viking’s GLP-1/GIP agonist advances through Phase 3 development
September 23, 2026
Drug Pipeline
Lilly and Novo set the backdrop for a changing obesity pipeline
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
August 4, 2026
Theme Survey
GLP-1 Shift: Branded Access and Oral Formulations Gain Ground